


PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/717,051
		Filing Date	11-20-2000
		Confirmation Number	2191
		First Named Inventor	M. South et al.
		Group Art Unit	TBA 1624
		Examiner Name	TBA
Sheet 1 of 2	Attorney Docket No. 3204/2 (4162.3)		



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
OK	1	5,656,645		Tamura et al.	08-12-1997
↓	2	5,658,930		Tamura et al.	08-19-1997
↓	3	6,011,158		Tamura et al.	01-4-2000

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
OK	4	WO	96/18644	A1	Corvas International Inc.	06-20-1996	x
↓	5	WO	97/46207	A2	Corvas International Inc.	12-11-1997	x
↓	6	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	x
↓	7	WO	00/69833	A1	Monsanto Company	11-23-2000	x

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
OK	8	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.	x	

Examiner Signature		Date Considered	8/6/04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/717,051
Filing Date	11-20-2000
Confirmation Number	2191
First Named Inventor	M. South et al.
Group Art Unit	TBA 1624
Examiner Name	TBA
Attorney Docket No.	3204/2 (4162.3)

Sheet 2 of 2

	9	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	x
--	---	--	---

Examiner
SignatureDate
Considered

8/6/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.




PTO/SB/08A				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/717,051
				Filing Date	11-20-2000
				Confirmation Number	2191
				First Named Inventor	M. South et al.
				Group Art Unit	TBA 1624
				Examiner Name	TBA
Sheet	1	of	4	Attorney Docket No.	3204/2 (4162.3)

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
OR	10	5,441,960	B1	Bernstein et al.	08-15-1995		
	11	5,668,289	B1	Sanderson et al.	09-16-1997		
	12	5,792,779	B1	Sanderson et al.	08-11-1998		
	13	5,861,380	B1	Gyorkos et al.	01-19-1999		
	14	5,866,573	B1	Sanderson et al.	02-02-1999		
	15	5,869,487	B1	Coburn et al.	02-09-1999		
	16	5,872,138	B1	Naylor-Olsen et al.	02-16-1999		
	17	6,037,356	B1	Lu et al.	03-14-2000		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
OR	18	EP	528 633	B1	Zeneca Limited	10-18-2000	
	19	EP	826 671	A1	The Green Cross Corporation	03-04-1998	
	20	EP	936 216	A1	Nippon Kayaku Kabushiki Kaisha	08-18-1999	
	21	EP	940 400	A1	Yoshitomi Pharmaceutical Industries, Ltd.	09-08-1999	
Examiner Signature				Date Considered	8/6/04		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/717,051
				Filing Date	11-20-2000
				Confirmation Number	2191
				First Named Inventor	M. South et al.
				Group Art Unit	TBA 1624
				Examiner Name	TBA
Sheet	2	of	4	Attorney Docket No.	3204/2 (4162.3)


OR	22	EP	997 474	A1	Pfizer Inc.	05-03-2000	
	23	WO	93/21214	A1	Zeneca Limited	10-28-1993	
	24	WO	96/33974	A1	The Green Cross Corporation (Abstract)	10-31-1996	
	25	WO	96/39380	A1	3-Dimensional Pharmaceuticals, Inc.	12-12-1996	
	26	WO	96/40100	A1	3-Dimensional Pharmaceuticals Inc.	12-19-1996	
	27	WO	97/01338	A1	Merk & Co., Inc.	01-16-1997	
	28	WO	97/30708	A1	Merck & Co., Inc.	08-28-1997	
	29	WO	97/40024	A1	Merck & Co., Inc.	10-30-1997	
	30	WO	98/08840	A1	Merck & Co., Inc.	03-05-1998	
	31	WO	98/09949	A1	Nippon Kayaku Kabushiki Kaisiia (Abstract)	03-12-1998	
	32	WO	98/10763	A1	Merck & Co., Inc.	03-19-1998	
	33	WO	98/16525	A1	Cor Therapeutics Inc.	04-23-1998	
	34	WO	98/16547	A1	Cor Therapeutics, Inc.	04-23-1998	
	35	WO	98/17274	A1	Merck & Co., Inc.	04-30-1998	
	36	WO	98/31670	A1	Merck & Co., Inc.	07-23-1998	
	37	WO	98/42342	A1	Merck & Co., Inc.	10-01-1998	
↓	38	WO	98/47876	A1	Akzo Nobel N.V.	10-20-1998	

Examiner Signature		Date Considered	8/6/04
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/717,051
				Filing Date	11-20-2000
				Confirmation Number	2191
				First Named Inventor	M. South et al.
				Group Art Unit	TBA 1624
				Examiner Name	TBA
Sheet	3	of	4	Attorney Docket No.	3204/2 (4162.3)


OK	39	WO	98/50420	A1	Akzo Nobel N.V.	11-12-1998	
	40	WO	99/00121	A1	Eli Lilly and Company	01-07-1999	
	41	WO	99/00126	A1	Eli Lilly and Company	01-07-1999	
	42	WO	99/00128	A1	Eli Lilly and Company	01-07-1999	
	43	WO	99/11267	A1	Merck & Co., Inc.	03-11-1999	
	44	WO	99/26920	A1	Corvas International, Inc.	06-03-1999	
	45	WO	99/36426	A1	Warner-Lambert Company	07-22-1999	
	46	WO	99/59591	A1	Merk & Co., Inc.	11-25-1999	
	47	WO	99/61442	A1	Merck & Co., Inc.	12-02-1999	
	48	WO	99/62538	A1	Cortech Inc.	12-09-1999	
	49	WO	99/64446	A1	3-Dimensional Pharmaceuticals Inc.	12-16-1999	
	50	WO	00/18762	A1	Merck & Co., Inc.	04-06-2000	
	51	WO	00/26210	A1	Merck & Co., Inc.	05-11-2000	
	52	WO	00/26211	A1	Merck & Co., Inc.	05-11-2000	
	53	WO	00/32574	A1	Sanofi-Synthelabo (Abstract)	06-08-2000	
	54	WO	00/39102	A1	Du Pont Pharmaceuticals Company	07-06-2000	
	55	WO	00/69826	A1	Monsanto Company	11-23-2000	
✓	56	WO	00/69832	A1	Monsanto Company	11-23-2000	

Examiner Signature		Date Considered	8/6/04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/717,051
				Filing Date	11-20-2000
				Confirmation Number	2191
				First Named Inventor	M. South et al.
				Group Art Unit	TBA 1624
				Examiner Name	TBA
Sheet	4	of	4	Attorney Docket No.	3204/2 (4162.3)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>DL</i>	57	SANDERSON, et al., "L-373,890, An Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12, pp 1497-1500, 1997.	

Examiner Signature	<i>Duyuk Bay</i>	Date Considered	8/6/04
-----------------------	------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/717,051
				Filing Date	November 20, 2000
				Confirmation Number	2191
				First Named Inventor	M. South
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket No.	3204/2 (PHA 162.3)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
DR	58	5,008,267		Katakami, et al.	04-16-1991


Examiner Signature	<i>Deepak Reng</i>	Date Considered	8/6/04
-----------------------	--------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.


PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/717,051
				Filing Date	November 20, 2000
				Confirmation Number	2191
				First Named Inventor	Michael S. South
				Group Art Unit	TBA 1624
				Examiner Name	TBA
Sheet	1	of	2	Attorney Docket No.	PHA 4162.3 (3204/2)

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
OR ↓	59	4,489,096	B1	Terao et al.	12-18-1984		
	60	4,851,413	B1	Terao et al.	07-25-1989		
	61	4,992,469	B1	Ozawa et al.	02-12-1991		
	62	5,304,658	B1	Terao et al.	04-19-1994		
	63	5,741,819	B1	Illig et al.	04-12-1998		
	64	6,180,627	B1	Blagg et al.	01-30-2001		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
OR ↓	65	DE	198 51 421	A1	Boehringer Ingelheim Pharma KG	05-11-2000	A
	66	EP	0 354 495	A1	Godecke Aktiengesellschaft	02-14-1990	A
	67	WO	98/09987	A1	Biochem Pharma, Inc.	03-12-1998	
	68	WO	99/43660	A1	Neurogen Corporation	09-02-1999	
	69	WO	99/48892	A1	Merck & Sharp & Dohme Limited	09-30-1999	
Examiner Signature				Date Considered	8/6/04		


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				Application Number	09/717,051
				Filing Date	November 20, 2000
				Confirmation Number	2191
				First Named Inventor	Michael S. South
				Group Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	2	Attorney Docket No.	PHA 4162.3 (3204/2)

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
OR	70	COBURN, C.A., "Small-molecule direct thrombin inhibitors 1997-2000." Expert Opinions on Therapeutic Patents, 2001, 721-738, Vol. 11, No. 5		
	71	XP-002182132 - DARVAS, et al., "Investigation of the Common Mechanism of Action of Antibacterial Compounds Containing .gamma.-pyridone-.beta.-carboxylic acid Structure by Principal Component." Arzneim.-Forsch., 1979, pp. 1334-1339, Vol. 29, 9.		
	72	XP-002172033 - KOHAMA et al., "Preparation of Piperidinyloxyacetylaminobenzoylalanine Derivatives and Analogs as Antithrombotics." JP 07,233,148.		
	73	XP-002187583 - MOERNER, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357.		
	74	PATEL et al., "Directed Aminomethylation of 3-Hydroxy-3(1H)-pyridinones and 3-hydroxy-4(1H)-pyridinones: Synthesis of iso-Deferiprone." Tetrahedron, 1996, pp. 1835-1840, Vol. 52, No. 5.		
	75	XP-002182410 - TRE COURT et al., "First Synthesis of (+)-harzianopyridone by Metalation of Polysubstituted O-pyridylcarbamates." J. Heterocycl. Chem., 1995, pp. 1117-1114, Vol. 32, No. 4.		
✓	76	TULINSKY et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93-100, Vol. 64, No. 1.		

Examiner Signature		Date Considered	8/6/04
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.